Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.

Cancer Epidemiology, published by ELSEVIER SCI LTD, serves as a premier platform for disseminating innovative research in the areas of cancer epidemiology and oncology. Operating from the Netherlands, this journal provides a critical insight into the factors influencing cancer incidence, including genetic, environmental, and lifestyle variables. With an impact factor reflecting its significance in the field, it holds a respectable Q2 ranking in Cancer Research, Epidemiology, and Oncology. The journal spans a wide range of topics and publishes studies that aim to bridge gaps in existing literature through rigorous research methodologies. Researchers and professionals interested in acquiring the latest insights and contributing to the evolving discourse on cancer epidemiology will find this journal an invaluable resource. Access to articles may be available through open access options, ensuring the widest dissemination of knowledge.

Familial Cancer is a premier journal dedicated to advancing the understanding of hereditary cancer, published by Springer. With an ISSN of 1389-9600 and E-ISSN 1573-7292, this journal serves as an essential platform for researchers and clinicians focused on the genetic predispositions to cancer and the implications for patient care. Since its inception in 2001, Familial Cancer has built a strong reputation, being consistently ranked in the Q2 category across several key research areas including Cancer Research, Genetics, and Oncology. As of 2023, it holds significant Scopus rankings, reflecting its impactful contributions in the fields of Medicine and Genetics, with a focus on clinical applications. The journal does not currently offer Open Access, emphasizing the commitment to rigorous peer review and high-quality publications. It is vital for emerging researchers and seasoned professionals alike, providing insights into the hereditary aspects of cancer and fostering developments that can lead to better prevention and therapeutic strategies.

Current Oncology Reports is a prestigious academic journal dedicated to the field of oncology, published by Springer and based in the United States. With an impressive impact factor and ranking as a Q1 journal in the 2023 category of Oncology, it positions itself among the top-tier publications within the discipline. Established in 1999, the journal has been a vital resource for researchers, professionals, and students alike, providing comprehensive insights and the latest advancements in cancer research and treatment. Through its rigorous peer-review process, Current Oncology Reports disseminates high-quality original articles, reviews, and clinical studies that foster collaboration and innovation in the oncology community. Although it currently operates under a subscription model, the journal remains committed to accessibility, ensuring that critical findings reach a broad audience. As such, it serves as an essential platform for those dedicated to the fight against cancer, making significant contributions to the evolving landscape of oncology.

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.

The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

Current Opinion in Supportive and Palliative Care, an esteemed journal published by Lippincott Williams & Wilkins, provides a vital platform for the dissemination of contemporary research and expert perspectives in the fields of supportive and palliative care. As part of the medical community's growing focus on critical care and oncology, this journal has earned its place in the Q2 category across multiple rankings, reflecting its influence and significance in advancing knowledge and practices. With its ISSN 1751-4258 and E-ISSN 1751-4266, it covers literature from 2007 to 2024, making it a reliable resource for the latest developments. While it does not offer open access, the journal ensures careful curating of high-quality articles, fostering a deeper understanding of complex care needs. Researchers, clinicians, and students alike will benefit from the journal's insights, exploring innovative strategies and multidisciplinary approaches to improve patient outcomes in critical situations. The commitment to such a crucial area of healthcare underscores the importance of this publication in shaping future practices and policies.